| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25c4fc4e202922a16436d7d118f2043e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2375f442ace98e41b53328749221b32b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50c393aedf7947b73ee322da82591561 |
| publicationDate |
2015-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015187130-A |
| titleOfInvention |
Combination therapy of afucosylated CD20 antibody with anti-VEGF antibody |
| abstract |
An afucosylated CD20 antibody used in combination therapy with an anti-VEGF antibody for the treatment of CD20-expressing cancer such as B-cell non-Hodgkin lymphoma (NHL), and the combination therapy. The afucosylated CD20 antibody is an afucosylated anti-CD20 antibody (especially humanized B-Ly1 antibody) whose fucose amount is 60% or less of the total amount of oligosaccharides (sugars) in Asn297, and the anti-VEGF antibody is The combination therapy which is bevacizumab, B20 series antibody or G6 series antibody. [Selection figure] None |
| priorityDate |
2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |